Effective Remission Induction in Children with Recurrent Acute Myeloid Leukemia by mAMSA, Ara-C, and VP 16

1987 ◽  
pp. 406-409
Author(s):  
F. Berthold ◽  
U. Creutzig ◽  
F. Lampert
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Remission Induction ◽  
Acute Myeloid

Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot study

2007 ◽  
Vol 87 (5) ◽  
pp. 361-367 ◽  
Author(s):  
Jerzy Hołowiecki ◽  
Sebastian Grosicki ◽  
Sławomira Kyrcz-Krzemien ◽  
Aleksander B. Skotnicki ◽  
Beata Piatkowska-Jakubas ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Pilot Study ◽  
Myeloid Leukemia ◽  
Remission Induction ◽  
Early Outcome ◽  
Refractory Acute Myeloid Leukemia ◽  
Adult Leukemia ◽  
Leukemia Group ◽  
Acute Myeloid

scholarly journals Remission induction in acute myeloid leukemia

2012 ◽  
Vol 96 (2) ◽  
pp. 164-170 ◽  
Author(s):  
Eytan M. Stein ◽  
Martin S. Tallman
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Remission Induction ◽  
Acute Myeloid

Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?

2018 ◽  
Vol 98 (3) ◽  
pp. 561-579 ◽  
Author(s):  
Ayman Qasrawi ◽  
Waled Bahaj ◽  
Lien Qasrawi ◽  
Omar Abughanimeh ◽  
John Foxworth ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Remission Induction ◽  
Acute Myeloid

scholarly journals The Expression Changes of CX3CL1 and Interlukin-6 Genes During Remission Induction Therapy in Patients With Acute Myeloid Leukemia

2021 ◽  
Vol 10 ◽  
pp. e2288
Author(s):  
Mahdiyar Iravani Saadi ◽  
Mani Ramzi ◽  
Aliasghar Karimi ◽  
Maryam Owjfard ◽  
Mahmoud Torkamani ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Induction Chemotherapy ◽  
Induction Therapy ◽  
Myeloid Leukemia ◽  
Hematologic Malignancy ◽  
Quantitative Polymerase Chain Reaction ◽  
Remission Induction ◽  
Response To Chemotherapy ◽  
Before And After ◽  
Acute Myeloid

Background: Acute Myeloid Leukemia syndrome (AML) is a hematologic malignancy which is due to clonal extensive proliferation of leukemic precursor cells and is rapidly fatal unless treated or response to chemotherapy. Cytogenetic findings have important role in prognosis and categorization of AML. The aim of this study was to investigate the expression changes in CX3CL1 and Interlukin-6 (IL-6) genes before and after chemotherapy as remission induction therapy in AML patients. Materials and Methods: In this study 69 patients (36 males, 33 female) with AML was selected from tertiary medical heath center. A quantitative polymerase chain reaction (PCR) was done for mRNA expression of CX3CL1 and IL-6genes before and after induction chemotherapy. To obtain expression changes in CX3CL1 and IL-6genes, we used 2-ΔΔCT method. Results: The expression of CX3CL1 and IL-6 was significantly increased after induction chemotherapy. Also, the ΔCt mean of CX3CL1 and IL-6 mRNA was not significant between AML subtype groups. Conclusion: In conclusion, as we showed that chemotherapy significantly increase the expression of CX3CL1 and IL-6 which can be used as a prognostic factor of AML.

scholarly journals Retrospective Evaluation of Patients with and without Primary Antifungal Prophylaxis During Remission Induction Chemotherapy in Patients with Acute Myeloid Leukemia

LLM Dergi ◽  
2020 ◽  
Vol 4 (1) ◽  
pp. 1-9
Author(s):  
Feyza MUTLAY ◽  
Ömür Gökmen SEVİNDİK ◽  
Şerife SOLMAZ ◽  
Celal ACAR ◽  
Sema ALPÇAVUŞ ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Induction Chemotherapy ◽  
Myeloid Leukemia ◽  
Antifungal Prophylaxis ◽  
Remission Induction ◽  
Retrospective Evaluation ◽  
Acute Myeloid

scholarly journals Comparative Study on the Infection Rates of Protected Environment versus Non-Protected Environment in Acute Myeloid Leukemia during Remission Induction Chemotherapy

2010 ◽  
Vol 27 (2) ◽  
pp. 113
Author(s):  
Se Hoon Sohn ◽  
Ha-young Lee ◽  
Dong Geun Kim ◽  
Sung Woo Park ◽  
Myung Jin Kim ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Comparative Study ◽  
Induction Chemotherapy ◽  
Myeloid Leukemia ◽  
Remission Induction ◽  
Infection Rates ◽  
Acute Myeloid

scholarly journals Acute Myeloid Leukemia and Acute Promyelocytic Leukemia

Hematology ◽  
2003 ◽  
Vol 2003 (1) ◽  
pp. 82-101 ◽  
Author(s):  
Bob Löwenberg ◽  
James D. Griffin ◽  
Martin S. Tallman
Keyword(s):  
Acute Myeloid Leukemia ◽  
Acute Promyelocytic Leukemia ◽  
Tyrosine Kinases ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Treatment Strategies ◽  
Promyelocytic Leukemia ◽  
Remission Induction ◽  
Novel Drugs ◽  
Acute Myeloid

Abstract The therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel drugs into the pipeline of clinical trials that target pathogenetic mechanisms of the disease. In Section I, Dr. Bob Löwenberg reviews current issues in the clinical practice of the management of adults with AML, including those of older age. Dr. Löwenberg describes upcoming possibilities for predicting prognosis in defined subsets by molecular markers and reviews experimental strategies to improve remission induction and postinduction treatment. In Section II, Dr. James Griffin reviews the mechanisms that lead to activation of tyrosine kinases by mutations in AML, the consequences of that activation for the cell, and the opportunities for targeted therapy and discusses some examples of developing novel drugs (tyrosine kinase inhibitors) and their effectiveness in AML (FLT3). In Section III, Dr. Martin Tallman describes the evaluation and management of patients with acute promyelocytic leukemia, a notable example of therapeutic progress in a molecularly defined entity of leukemia. Dr. Tallman focuses on the molecular genetics of APL, current curative treatment strategies and approaches for patients with relapsed and refractory disease. In addition, areas of controversy regarding treatment are addressed.

Sign in / Sign up

Export Citation Format

Share Document